These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 19539430

  • 1. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.
    Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N.
    Cancer Treat Rev; 2009 Nov; 35(7):570-3. PubMed ID: 19539430
    [Abstract] [Full Text] [Related]

  • 2. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP.
    J Natl Cancer Inst; 2006 Nov 15; 98(22):1655-63. PubMed ID: 17105988
    [Abstract] [Full Text] [Related]

  • 3. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data.
    Polyzos NP, Pavlidis N, Paraskevaidis E, Ioannidis JP.
    Eur J Cancer; 2006 Feb 15; 42(3):319-26. PubMed ID: 16376072
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.
    Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP, MAC-NPC Collaborative Group.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):47-56. PubMed ID: 16377415
    [Abstract] [Full Text] [Related]

  • 5. [Meta-analysis of the efficacy of transcatheter arterial chemoembolization combined with percutaneous ethanol injection in treating unresectable primary liver cancer].
    Gu GW, Li XC.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 31; 89(12):805-9. PubMed ID: 19595117
    [Abstract] [Full Text] [Related]

  • 6. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of cancer of unknown primary, today and future].
    Shibata H.
    Gan To Kagaku Ryoho; 2009 Jun 01; 36(6):918-22. PubMed ID: 19542712
    [Abstract] [Full Text] [Related]

  • 8. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Kato S, Yasuda K, Nishino Y, Ohori H, Takahashi M, Takahashi S, Yamaura G, Ohtsuka K, Kakudo Y, Chiba N, Shimodaira H, Sakayori M, Kato S, Suzuki T, Murakawa Y, Gamoh M, Shibata H, Yoshioka T, Ishioka C.
    Gan To Kagaku Ryoho; 2007 Aug 01; 34(8):1227-31. PubMed ID: 17687203
    [Abstract] [Full Text] [Related]

  • 9. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.
    Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J.
    Anticancer Res; 2009 Jul 01; 29(7):2739-45. PubMed ID: 19596954
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
    Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N.
    Crit Rev Oncol Hematol; 2012 Nov 01; 84(2):213-23. PubMed ID: 22503530
    [Abstract] [Full Text] [Related]

  • 12. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials.
    Dagres N, Varounis C, Flevari P, Piorkowski C, Bode K, Rallidis LS, Tsougos E, Leftheriotis D, Sommer P, Hindricks G, Kremastinos DT.
    Am Heart J; 2009 Jul 01; 158(1):15-20. PubMed ID: 19540387
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis.
    Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, Lee KB, Kang JH, Park BJ.
    Br J Cancer; 2013 Jan 15; 108(1):39-48. PubMed ID: 23175147
    [Abstract] [Full Text] [Related]

  • 17. Forty years experience of treating cancer of unknown primary.
    Pavlidis N.
    Acta Oncol; 2007 Jan 15; 46(5):592-601. PubMed ID: 17562435
    [Abstract] [Full Text] [Related]

  • 18. Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" study.
    Sève P, Mackey J, Sawyer M, Lesimple T, de La Fouchardière C, Broussolle C, Dumontet C, Ray-Coquard I.
    Bull Cancer; 2009 Apr 15; 96(4):E7-17. PubMed ID: 19435692
    [Abstract] [Full Text] [Related]

  • 19. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G, Greco FA, Pavlidis N.
    Cancer Treat Rev; 2009 May 15; 35(3):221-7. PubMed ID: 19046817
    [Abstract] [Full Text] [Related]

  • 20. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
    Rondeau V, Michiels S, Liquet B, Pignon JP.
    Stat Med; 2008 May 20; 27(11):1894-910. PubMed ID: 18069745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.